RBC Capital analyst Luca Issi maintained a Buy rating on Ionis Pharmaceuticals (IONS - Research Report) on November 9 and set a price target of $64.00. The company's shares closed yesterday at $45.47.Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Bluebird Bio, and Arrowhead Pharmaceuticals. According to TipRanks, Issi has an average return of -18.5% and a 26.97% success rate on recommended stocks. In addition to RBC Capital, Ionis Pharmaceuticals also received a Buy from BMO Capital's Gary Nachman in a report issued yesterday. However, on the same day, Barclays maintained a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).
https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-buy-rating-for-ionis-pharmaceuticals-ions?utm_source=advfn.com&utm_medium=referral